This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

10 Most Shorted Stocks in Biotech

Content on this page requires a newer version of Adobe Flash Player.

Get Adobe Flash player

Seattle Genetics (SGEN - Get Report)

Short interest: 26%
52-week high: $19.42
Current price: $19.04
Year-to-date performance relative to the Nasdaq Biotechnology Index: Up 27%

The market opportunity for the newly launched Adcetris in relapsed and refractory Hodgkin's lymphoma is much smaller than Seattle Genetics' executives and bullish analysts forecast. Recent sell-side surveys of lymphoma doctors claim to have found enough eligible patients to predict a successful Adcetris launch. These reports have helped Seattle Genetics' stock price recover from the August lows following the market collapse. Hedge-fund shorts have done doctor surveys of their own which reveal the opposite -- too few Hodgkin's patients -- and they're betting that Seattle Genetics' stock price will fall again.

Even if Seattle Genetics puts up early strong Adcetris sales numbers in the third and fourth quarters, it will be more likely due to inventory stocking and a backlog of advanced Hodgkin's patients who were waiting for treatment. Once that initial bolus of patients is treated, Adcetris sales will fall off a cliff. And moving Adcetris into earlier-stage Hodgkin's will be very difficult because the standard drug therapy used today is already highly effective, with response rates hovering near 90%.

Shorts also point to Seattle Genetics' decision to prevent distributors from reporting monthly Adcetris sales figures to IMS Health as a red flag suggesting the company is nervous about the drug's commercial trajectory.
4 of 11

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
BPAX $55.05 -1.24%
SVNT $0.00 0.00%
AVNR $16.96 0.00%
ONTY $3.53 5.10%
SGEN $41.25 2.50%

Markets

Chart of I:DJI
DOW 16,654.77 +369.26 2.27%
S&P 500 1,987.66 +47.15 2.43%
NASDAQ 4,812.7080 +115.1720 2.45%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs